Oro Valley, AZ (PRWEB) June 26, 2013
Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, has announced the release of a comprehensive report on the company, compiled by Crystal Research Associates, LLC. The Executive Informational Overview, released on June 17, 2013, details several key points regarding Convoy Therapeutics. Areas covered in the report include recent financial data, growth strategies, patents and other intellectual property, as well as a general overview of the company and its management.
As a transdermal penetration system, the Convoy Therapeutics technology offers a unique delivery option due to its "plug and play" capability. This allows the company to readily reformulate existing molecules (approved and otherwise) increasing skin penetration by orders of magnitude compared to competing technologies. This reduces time to market and improves the patient experience, decreasing dosing regimens and increasing patient compliance.